The intended collaboration aims to help improve patient care
by enhancing next-generation sequencing research for cancer care
and expanding data sources for precision medicine.
BOSTON, ALISO VIEJO, Calif. and LAUSANNE, Switzerland, March 14,
2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH) and
REALM IDx announced today that they signed a letter of intent to
collaborate in the co-development of novel genomic applications and
commercialization of multi-modal applications. Together, the
companies aim to expand next-generation sequencing (NGS) research
for cancer care and develop new multi-modal data streams to improve
patient outcomes. The companies expect to enter into a definitive
collaboration agreement following further discussion.
NGS is becoming the new standard of care in cancer diagnostics,
particularly as novel therapies require genomic information to be
prescribed in a personalized way. With the intended
collaboration, SOPHiA GENETICS and REALM IDx's endeavor is
to enrich and scale the analysis of NGS assays, including
Homologous Recombination Deficiency (HRD). Assessments can leverage
TumorNEXT-HRD, a product of Ambry Genetics, a subsidiary of REALM
IDx. SOPHiA GENETICS and REALM IDx also expect to explore the
potential for increasing diagnostic insights by combining Ambry
Genetics' Variant Assessment database (AVA) with SOPHiA GENETICS'
SOPHiA DDM (Data-Driven Medicine) platform for HRD detection.
"SOPHiA GENETICS' mission is to advance data-driven medicine to
improve health outcomes worldwide. We want to bring together our
global SOPHiA DDM platform, powered by AI and machine learning,
with REALM IDx's cancer screening capabilities and early detection
diagnostics. Our goal is to enable health care professionals to
leverage insights across multiple data sources with the aim to
provide better diagnosis and treatments for the benefit of patients
around the world," said Jurgi Camblong, co-founder and CEO,
SOPHiA GENETICS.
SOPHiA GENETICS and REALM IDx also share an interest in bringing
together genomics, radiology, and pathology data, combined with
artificial intelligence, to generate actionable insights. While
REALM IDx's subsidiary Ambry Genetics has focused on screening and
early detection diagnostics in pancreatic and breast cancers,
SOPHiA GENETICS' focus has been on prediction response models in
advanced stage cancers, such as lung cancer. The companies hope
that synergies between SOPHiA GENETICS and REALM IDx may provide
opportunities to explore combining data sources and
capabilities in the multimodal space, potentially creating a
roadmap for comprehensive oncology applications.
As part of the intended collaboration, SOPHiA GENETICS may
use Ambry Genetics' lab for their sequencing needs. The companies
believe that the combination of Ambry Genetics' decades of
leadership in clinical next-generation sequencing and translational
analysis and the SOPHiA DDM cloud-based analytics platform, can
support improved clinical research decisions by pharmaceutical
companies.
"The heart of our work is the ability to combine patient data
from multiple sources to improve treatment decisions and discover
new medicines," said Jonathan Usuka,
Ph.D., chief strategy and informatics officer of REALM IDx. "With
the synergies we hope to realize from collaborating with SOPHiA
GENETICS, we will continue to enhance our ability to address some
of health care's most challenging diseases."
About REALM IDx
REALM IDx, Inc. is a health care
company pioneering in the field of Integrated Diagnostics (IDx), an
advanced field of clinical science that brings together laboratory
medicine, radiology, pathology and sophisticated artificial
intelligence to derive actionable insights to predict, diagnose and
treat disease. Powered by proprietary software platforms,
industry-leading genomics technology from Ambry Genetics
Corporation and radiology and pathology services from Invicro, LLC,
the company is equipped to collect, analyze and report on
multi-modal precision diagnostic data sets. REALM's extensive
network of health care providers and pharmaceutical partners will
drive clinical access to innovations that lead to better medical
solutions for patient care. To learn more, visit REALMIDx.com.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH)
is a health care technology company dedicated to establishing the
practice of data-driven medicine as the standard of care and for
life sciences research. It is the creator of the SOPHiA DDM™
Platform, a cloud-based SaaS platform capable of analyzing data and
generating insights from complex multimodal data sets and different
diagnostic modalities. The SOPHiA DDM™ Platform and related
solutions, products and services are currently used by more than
790 hospital, laboratory, and biopharma institutions globally. For
more information, visit SOPHiAGENETICS.COM, or connect on Twitter,
LinkedIn and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenertics.com to obtain
the appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking Statements:
This
press release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations and financial position,
business strategy, products and technology, as well as plans and
objectives of management for future operations, are forward-looking
statements. Forward-looking statements are based on our
management's beliefs and assumptions and on information currently
available to our management. Such statements are subject to risks
and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to
various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given
that such future results will be achieved. Such forward-looking
statements contained in this press release speak only as of the
date hereof . We expressly disclaim any obligation or undertaking
to update these forward-looking statements contained in this press
release to reflect any change in our expectations or any change in
events, conditions, or circumstances on which such statements are
based, unless required to do so by applicable law. No
representations or warranties (expressed or implied) are made about
the accuracy of any such forward-looking statements.
Logo
- https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg